An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Precision BioSciences to Provide an Update on its Ongoing Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on Wednesday, June 8, 2022
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Precision BioSciences, Inc. (Nasdaq: DTIL) announced a webcast and conference call on June 8, 2022, at 8:00 AM ET to update on its allogeneic CAR T programs. The company aims to share the latest clinical data on its lead candidate, PBCAR0191, designed for patients who have relapsed after CAR T therapy. Chief Medical Officer Alan List emphasized the significant unmet need in the CAR T relapse area.
Precision BioSciences is focused on developing innovative gene editing therapies using ARCUS technology to address genetic disorders and enhance patient treatment options.
Positive
Upcoming webcast on clinical updates for PBCAR0191 scheduled for June 8, 2022.
Focus on addressing unmet needs in CAR T relapse patients, indicating potential market opportunity.
Development of a promising first-in-class allogeneic CAR T program could enhance treatment options.
Negative
Lack of specific financial metrics in the announcement raises concerns about overall company performance.
No immediate data on clinical outcomes for PBCAR0191, leaving uncertainty about its efficacy.
DURHAM, N.C.--(BUSINESS WIRE)--
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will share an update on its allogeneic CAR T programs during a company-hosted webcast and conference call on June 8, 2022 at 8:00 AM ET.
"We look forward to sharing the recent developments on our CAR T programs, including the latest clinical data on our potential first-in-class allogeneic CAR T program, PBCAR0191, in patients who relapsed following CAR T treatment," said Alan List, M.D., Chief Medical Officer at Precision BioSciences. “The CAR T relapse setting is a rapidly growing area with dire unmet medical need that is not adequately addressed by current treatment options.”
Company-Hosted Webcast and Conference Call Information
Precision will host a conference call and webcast on Wednesday, June 8, 2022 at 8:00 AM ET to review its ongoing allogeneic CAR T programs. The dial-in conference call numbers for domestic and international callers are (866) 996-7202 and (270) 215-9609, respectively. The conference ID number for the call is 5754683. Participants may access the live webcast, and accompanying presentation materials, as well as the archived webcast on Precision’s website in the Investors section under Events & Presentations: https://investor.precisionbiosciences.com/events-and-presentations.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple ex vivo “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
When will Precision BioSciences provide an update on its CAR T programs?
Precision BioSciences will share an update on its CAR T programs during a webcast and conference call on June 8, 2022, at 8:00 AM ET.
What is PBCAR0191?
PBCAR0191 is Precision BioSciences' lead allogeneic CAR T candidate aimed at treating patients who have relapsed after previous CAR T therapy.
What are the key focus areas for Precision BioSciences?
Precision BioSciences focuses on developing ex vivo allogeneic CAR T and in vivo gene editing therapies using its ARCUS technology.
Who is leading the development of CAR T programs at Precision BioSciences?
Alan List, M.D., serves as the Chief Medical Officer at Precision BioSciences and is leading the CAR T program developments.
What is the significance of the CAR T relapse setting mentioned in the press release?
The CAR T relapse setting represents a critical area with significant unmet medical needs, which Precision BioSciences aims to address with its therapies.
